

Active substances set

Search phrase: axitinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Kidney cancer

Axitinib

Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO